Epcoritamab Slashes Lymphoma Risk, Boosts Genmab Stock

Genmab (GMAB) shares jumped 3.5% in after-hours trading Monday after its Phase 3 EPCORE DLBCL-4 trial showed a 60% reduction in disease progression risk for relapsed lymphoma patients, a result that opens a potential new regulatory filing and commercial expansion with partner AbbVie.

For investors tracking near-term catalysts, the data materially de-risks epcoritamab’s commercial trajectory in diffuse large B-cell lymphoma (DLBCL), the most common non-Hodgkin lymphoma subtype, and strengthens the asset’s valuation case heading into regulatory discussions.

Key Takeaways

Trial met primary goal: HR 0.40, a 60% cut in progression risk.
GMAB gained 3.5% after hours; regular session closed down 0.38%.
Genmab and AbbVie to engage global regulators on trial results.

Market Reaction & Context

GMAB closed the regular session at $26.02, down 0.38%, before the after-hours move to $26.94 – a gain of roughly $0.92, or 3.52% ¹. The after-hours print compares favourably with the broader biotech sector’s muted Monday session, with the Nasdaq Composite adding 2.07% on the day, driven largely by communication services and technology names rather than healthcare.

Epcoritamab already holds regulatory approval in certain lymphoma indications across more than 65 territories – branded EPKINLY in the U.S. and Japan and TEPKINLY in the EU – giving the new data an established commercial platform to build upon ¹.

Trial Data: What the Numbers Show

The EPCORE DLBCL-4 study evaluated epcoritamab combined with lenalidomide versus standard-of-care in adult patients with relapsed or refractory DLBCL who had received at least one prior line of therapy ¹. The combination is chemotherapy-free, a structural differentiator in a space historically dominated by aggressive regimens.

The hazard ratio of 0.40 (95% CI: 0.30-0.55) reflects a statistically significant and clinically meaningful improvement in progression-free survival ¹. The trial, a global Phase 3 open-label, multi-centre, randomised study, began August 13, 2024, and remains ongoing.

DLBCL accounts for approximately 25-30% of all non-Hodgkin lymphoma cases worldwide, with roughly 25,000 new diagnoses annually in the U.S. alone – a market size that underpins the commercial significance of any label expansion ¹.

Regulatory & Commercial Outlook

Genmab and AbbVie said they plan to engage with global regulatory authorities on the EPCORE DLBCL-4 results and will present detailed data at a future medical meeting ¹. No specific filing timeline was provided.

“The study met its primary objective, demonstrating a 60% reduction in the risk of disease progression and death,” the companies said in their topline readout, adding that the result showed “statistically significant and clinically meaningful improvement in progression-free survival.” ¹

The co-development structure splits commercial responsibilities in the U.S. and Japan between both companies, while AbbVie handles broader global commercialization – a split that limits Genmab’s direct revenue upside in ex-U.S. markets but reduces execution risk ¹.

Valuation Catalyst Assessment

For deal-focused investors, the DLBCL-4 data represents a binary catalyst that has now resolved positively, shifting attention to the regulatory timeline and any potential label-expansion royalty flows. The 3.5% after-hours move is relatively modest given the magnitude of the efficacy data, suggesting the market may be waiting for a confirmed regulatory submission before repricing the asset more aggressively.

Epcoritamab is a T-cell engaging bispecific antibody administered subcutaneously – a delivery method that supports outpatient use and could widen the addressable treatment setting compared to intravenous alternatives ¹.

Conclusion

The EPCORE DLBCL-4 readout removes a key clinical uncertainty for GMAB and positions epcoritamab for a potential new regulatory submission in second-line-plus DLBCL. With the underlying data strong and regulatory engagement confirmed, the next price-action catalyst is likely a filing confirmation or a high-profile data presentation at a major oncology congress.

Not investment advice. For informational purposes only.